rac cis-Moxifloxacin-d4 hydrochloride(Synonyms: 盐酸莫西沙星 d4 (盐酸盐))

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
rac cis-Moxifloxacin-d4 hydrochloride (Synonyms: 盐酸莫西沙星 d4 (盐酸盐))

rac cis-Moxifloxacin-d4 hydrochloride 是 Moxifloxacin hydrochloride 的氘代物。Moxifloxacin Hydrochloride (BAY 12-8039) 是一种口服有效的 8-甲氧基喹诺酮类抗菌药物，用于急性细菌性鼻窦炎，慢性支气管炎的急性细菌性加重和感染性肺炎的研究。

rac cis-Moxifloxacin-d4 hydrochloride(Synonyms: 盐酸莫西沙星 d4 (盐酸盐))

rac cis-Moxifloxacin-d4 hydrochloride Chemical Structure

CAS No. : 1217802-65-7

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

rac cis-Moxifloxacin-d4 hydrochloride is the deuterium labeled Moxifloxacin hydrochloride. Moxifloxacin Hydrochloride (BAY 12-8039) is an oral 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

441.92

Formula

C21H21D4ClFN3O4
CAS 号

1217802-65-7
中文名称

盐酸莫西沙星 d4 (盐酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Culley CM, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm. 2001 Mar 1;58(5):379-88.

    [3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39.

    [4]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702.

    [5]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务